Pieris Pharmaceuticals Inc. (PIRS) and Neurotrope Inc. (NASDAQ:NTRP) Contrasting side by side

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) and Neurotrope Inc. (NASDAQ:NTRP) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pieris Pharmaceuticals Inc. 33.49M 6.36 28.39M -0.51 0.00
Neurotrope Inc. N/A 0.00 13.72M -1.47 0.00

Demonstrates Pieris Pharmaceuticals Inc. and Neurotrope Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals Inc. -84.77% 0% 0%
Neurotrope Inc. 0.00% -77.2% -70.4%

Volatility & Risk

Pieris Pharmaceuticals Inc. is 71.00% more volatile than Standard & Poor’s 500 because the company has a beta of 1.71. Neurotrope Inc.’s 178.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 2.78 beta.

Liquidity

Pieris Pharmaceuticals Inc. has a Current Ratio of 3 and a Quick Ratio of 3. Competitively, Neurotrope Inc.’s Current Ratio is 23.1 and has 23.1 Quick Ratio. Neurotrope Inc.’s better ability to pay short and long-term obligations than Pieris Pharmaceuticals Inc.

Analyst Recommendations

Pieris Pharmaceuticals Inc. and Neurotrope Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Pieris Pharmaceuticals Inc. 0 0 1 3.00
Neurotrope Inc. 0 0 0 0.00

Pieris Pharmaceuticals Inc.’s upside potential is 15.47% at a $5 average target price.

Insider & Institutional Ownership

Roughly 72% of Pieris Pharmaceuticals Inc. shares are held by institutional investors while 13.4% of Neurotrope Inc. are owned by institutional investors. Pieris Pharmaceuticals Inc.’s share held by insiders are 0.23%. Insiders Competitively, held 18.97% of Neurotrope Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pieris Pharmaceuticals Inc. 24.76% 24.76% 33.33% 8.99% -32.4% 45.86%
Neurotrope Inc. 2.4% 27.87% 70.99% 4.02% -19.44% 103.08%

For the past year Pieris Pharmaceuticals Inc.’s stock price has smaller growth than Neurotrope Inc.

Summary

Pieris Pharmaceuticals Inc. beats on 6 of the 10 factors Neurotrope Inc.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universität München; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The companyÂ’s lead product candidate is bryostatin-1, a natural product isolated from a marine invertebrate organism, which is in a Phase II trial for the treatment of moderate to severe AlzheimerÂ’s dementia, as well as in preclinical studies as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease, and Rett Syndrome. It has a license agreement with the Leland Stanford Junior University to sublicense Bryologs that are structural derivatives of Bryostatin for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate, NRV II, LLC. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.